Novo Nordisk A/S
Novo Nordisk A/S (ticker: NVO) is a global pharmaceutical company best known for its leadership in diabetes care, with growing exposure to obesity treatments and haemophilia. The company combines strong brand recognition, scale in insulin production and a pipeline of GLP-1 therapies to drive revenue and margins. Investors typically watch its sales growth in GLP-1 and insulin segments, R&D progress, pricing and reimbursement dynamics in key markets, and manufacturing capacity. With a market capitalisation of about $187.6 billion, Novo Nordisk is a large-cap healthcare name often viewed for income and growth characteristics, though it can be sensitive to regulatory decisions and competition. This summary is for educational purposes only and is not personal investment advice; suitability depends on an investor’s objectives, timeframe and risk tolerance. Past performance is not a guide to future results and share prices can fall as well as rise.
Why It's Moving
Novo Nordisk eyes blockbuster Q4 boost from Ozempic and Wegovy's surging sales amid oral pill milestone.
- Ozempic and Wegovy raked in DKK 152.5 billion through nine months of 2025, underscoring their dominance in diabetes and obesity markets with key label expansions for cardiovascular and kidney benefits.
- FDA approval and early January commercial launch of oral Wegovy pill beats rivals like Eli Lilly, offering easier administration to expand patient access and sales.
- Upcoming Q4 results anticipated at $0.91 EPS and $12.11B revenue, with analysts watching label expansions for higher-dose Wegovy and Ozempic in peripheral artery disease.
Novo Nordisk eyes blockbuster Q4 boost from Ozempic and Wegovy's surging sales amid oral pill milestone.
- Ozempic and Wegovy raked in DKK 152.5 billion through nine months of 2025, underscoring their dominance in diabetes and obesity markets with key label expansions for cardiovascular and kidney benefits.
- FDA approval and early January commercial launch of oral Wegovy pill beats rivals like Eli Lilly, offering easier administration to expand patient access and sales.
- Upcoming Q4 results anticipated at $0.91 EPS and $12.11B revenue, with analysts watching label expansions for higher-dose Wegovy and Ozempic in peripheral artery disease.
When is the next earnings date for Novo Nordisk A/S (NVO)?
Novo Nordisk is scheduled to announce its Q4 2025 earnings results on February 4, 2026 before the opening of the NASDAQ Copenhagen stock exchange. An earnings conference call will follow the announcement at 13:00-14:00 CET (12:00-13:00 GMT / 07:00-08:00 EST). This earnings report will cover the full-year 2025 financial performance, providing investors with comprehensive annual results and management guidance for the year ahead.
Stock Performance Snapshot
Analyst Rating
Analysts suggest keeping Novo Nordisk's stock as it may not significantly increase in value.
Financial Health
Novo Nordisk is showing strong profits, cash flow, and revenue, indicating robust financial performance.
Dividend
Novo Nordisk's average dividend yield of 2.95% offers moderate income for investors seeking dividends. If you invested $1000 you would be paid $28.50 a year in dividends (based on the last 12 months).
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NVO
Healthcare Titans: Brazil Growth vs Currency Volatility
Brazil's healthcare sector is rapidly modernizing, creating significant demand for global innovation in areas like AI and digital health. This basket offers exposure to the US and EU-listed pharmaceutical, medical device, and technology titans that supply this growing market.
Published: October 14, 2025
Explore BasketNovo Nordisk Stock Risks: Healthcare Diversification
As Africa's healthcare needs grow, demand for innovative treatments for chronic conditions like diabetes is on the rise. This basket offers potential exposure to this trend through leading global pharmaceutical and healthcare companies listed on US and EU exchanges.
Published: September 23, 2025
Explore BasketJohnson & Johnson (Healthcare Diversification)
As Nigeria's population seeks stable growth opportunities, the global healthcare sector offers a compelling theme for portfolio diversification. This basket provides exposure through a collection of US and EU-listed industry leaders in pharmaceuticals, medical devices, and consumer health.
Published: September 16, 2025
Explore BasketObesity Treatment (Pharma Giants vs Biotech Firms)
Novo Nordisk's major restructuring, driven by intense competition from Eli Lilly, highlights the high-stakes battle in the weight-loss drug market. This theme focuses on other pharmaceutical companies that could benefit from this rivalry, either as innovators with next-generation treatments or as potential acquisition targets.
Published: September 10, 2025
Explore BasketCardio-Metabolic Drugs: Beyond Weight Loss Benefits
Following new data showing Novo Nordisk's Wegovy has superior cardiovascular benefits over a key rival, the competitive landscape for weight-loss drugs has intensified. This theme focuses on the pharmaceutical giants battling for dominance and the innovative biotechs whose research in related metabolic and cardiovascular fields is now more valuable than ever.
Published: September 1, 2025
Explore BasketBeyond The Needle: The Oral GLP-1 Revolution
Eli Lilly's successful trial of its oral weight-loss drug, orforglipron, signals a major shift in the treatment landscape for obesity and diabetes. This theme focuses on the innovative pharmaceutical companies developing the next wave of convenient, non-injectable therapies poised to challenge the dominance of current market leaders.
Published: August 28, 2025
Explore BasketOral Obesity Treatments: Beyond The Needle
Following successful Phase 3 trials for its oral weight-loss drug, orforglipron, Eli Lilly is positioned to enter the lucrative obesity treatment market. This development creates a new investment theme focused on pharmaceutical companies developing patient-friendly, oral alternatives to injectable GLP-1 therapies.
Published: August 27, 2025
Explore BasketWhich Pharma Stocks Could Follow Wegovy's Success?
Following the FDA's approval of Novo Nordisk's Wegovy for a common liver disease, this theme focuses on pharmaceutical companies developing treatments for metabolic disorders. This development opens a new market for weight-loss drugs and signals opportunity for firms with therapies targeting related conditions.
Published: August 21, 2025
Explore BasketGLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Published: August 19, 2025
Explore BasketPharma's Digital Prescription
Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.
Published: August 19, 2025
Explore BasketExecutive Conviction In The GLP-1 Market
Following a stock drop from a clinical trial setback, Eli Lilly executives made significant share purchases, signaling strong belief in the company's future. This insider confidence highlights a potential investment opportunity in the rapidly growing and competitive GLP-1 weight-loss drug market.
Published: August 13, 2025
Explore BasketHypertension Therapy Innovators
This carefully selected group of stocks represents companies at the forefront of developing breakthrough treatments for hypertension, a condition affecting over a billion people worldwide. Following AstraZeneca's groundbreaking trial results, these pharmaceutical innovators are positioned to potentially transform cardiovascular medicine and address a massive unmet medical need.
Published: July 15, 2025
Explore BasketEarnings Over Headwinds
A carefully selected collection of companies showing exceptional earnings growth despite market challenges. These stocks were handpicked by our analysts for their ability to maintain strong performance even when facing trade tensions and economic uncertainty.
Published: July 2, 2025
Explore BasketTop Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Published: May 29, 2025
Explore BasketFuture Tech: World Changing Ideas
Get ahead of tomorrow's innovations with this collection of stocks pushing technological boundaries. Our analysts have carefully selected companies developing flying cars, breakthrough medical treatments, and robotic surgery that could reshape our future.
Published: May 25, 2025
Explore BasketPharma
Health is wealth, and these carefully selected pharmaceutical companies could help your portfolio grow. Our professional analysts have handpicked these stocks from an industry that's projected to reach $1.9 trillion by 2027.
Published: May 6, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Diabetes market leader
Strong positions in insulin and GLP‑1 products underpin revenue; however, growth can be affected by competition and reimbursement changes.
Global market reach
Broad geographic presence and manufacturing scale help resilience, though exposure to policy and pricing shifts across regions adds uncertainty.
Pipeline and innovation
A busy R&D pipeline in obesity and other areas offers upside potential, while clinical and regulatory setbacks remain possible.
Compare Novo Nordisk with other stocks
Eli Lilly vs Novo Nordisk
Eli Lilly vs Novo Nordisk: A Stock Comparison
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
Amneal Pharmaceuticals Inc.
Amneal Pharmaceuticals Inc. is an integrated generic and specialty pharmaceutical company that develops, manufactures, and markets generic and specialty pharmaceutical products.
